AMAG : Summary for AMAG Pharmaceuticals, Inc. - Yahoo Finance

U.S. Markets close in 33 mins.

AMAG Pharmaceuticals, Inc. (AMAG)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
21.67-0.08 (-0.34%)
As of 3:26PM EDT. Market open.
People also watch
ACORALNYANACAKRXMNTA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close21.75
Open21.75
Bid21.80 x 300
Ask21.85 x 1000
Day's Range21.27 - 22.30
52 Week Range17.92 - 36.83
Volume866,707
Avg. Volume1,343,953
Market Cap744.31M
Beta0.78
PE Ratio (TTM)-301.04
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Billionaires' Worst Healthcare Stock Picks for 2017 (So Far)
    Motley Foolyesterday

    Billionaires' Worst Healthcare Stock Picks for 2017 (So Far)

    Endo International, Genesis Healthcare, AMAG Pharmaceuticals, and MannKind haven't paid off so far this year.

  • AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : March 21, 2017
    Capital Cube2 days ago

    AMAG Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AMAG-US : March 21, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for AMAG Pharmaceuticals, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving ... Read more (Read more...)

  • Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women
    PR Newswire3 days ago

    Palatin Technologies Receives Notice of Allowance on Bremelanotide Methods of Use Patent for Treatment of Hypoactive Sexual Desire Disorder in Premenopausal Women

    CRANBURY, N.J., March 20, 2017 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 14/704,223. The allowed claims are for methods of treating female sexual dysfunction and hypoactive sexual desire disorder (HSDD) with bremelanotide, an investigational product designed for on-demand treatment of HSDD in premenopausal women. Once issued, the patent will have a term to November 2033.